APR 8·Streetwise Reports▲
California Biotech Co. Advances Depression Drug Breakthrough
Alto Neuroscience Inc. (ANRO:NYSE) is shifting its focus to ALTO-207, a drug targeting treatment-resistant depression, after mixed results from its ALTO-101 trial for cognitive impairment associated with schizophrenia. Despite the ALTO-101 setback, the company is moving forward with ALTO-207, planning a Phase 2b clinical trial, and has garnered 'Buy' and 'Outperform' ratings from multiple analysts who see significant market potential in addressing mental health conditions. The global market for psychotropic medications is projected to reach US$30 billion by 2030, driven by increased prevalence of mood disorders and improved diagnostics.
MAR 27·Stock Titan→
[DEF 14A] Alto Neuroscience, Inc. Defin...
Alto Neuroscience, Inc. is holding its 2026 annual meeting on May 12, 2026, where stockholders will vote on several key proposals, including the election of two Class II directors, the ratification of Deloitte & Touche LLP as the independent auditor, and amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan. The proposed amendments aim to adjust the "evergreen" formulas in the equity plans to include pre-funded warrants in the calculation of annual share reserve increases, aligning with a recent securities purchase agreement. The Board recommends voting "FOR" all four proposals, emphasizing the importance of these changes for long-term equity flexibility and employee incentives.
